Clinical trials: High-risk Neuroblastoma
Neuroblastoma, High-Risk
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
This is a phase I study. The purpose of this study is to see if it is safe and feasible to give the participant cyclophosphamide (a type of chemotherapy), natural killer (NK) cells, and an antibody called Hu3F8 as a treatment for…
- Trial name
- NCT02650648
- Testing
- cyclophosphamide, NK cells, hu3F8
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk…
- Trial name
- HR-NBL2 (NCT04221035)
- Testing
- Vincristine, Carboplatin, Etoposide
- Where
- 142 sites in Australia, Austria and 18 more
- Volunteers
- 800 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
High-risk Neuroblastoma
Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma
This was an open-label, multi-center, single-arm, Phase 1 study. The purpose of this study was for evaluating the safety and pharmacokinetics of dinutuximab beta as maintenance therapy in Chinese participants with high-risk…
- Trial name
- NCT05373901
- Testing
- Dinutuximab Beta, 13-cis-Retinoic Acid
- Where
- 3 sites in China
- Volunteers
- 8 people
- Sponsor
- BeiGene
Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
This phase II trial tests how well defibrotide works in preventing transplant-associated thrombotic microangiopathy (TA-TMA) in patients with high-risk neuroblastoma undergoing tandem transplants (hematopoietic stem cell…
- Conditions
- Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma, High-risk Neuroblastoma, Thrombotic Microangiopathies
- Trial name
- NCT06182410
- Testing
- Defibrotide
- Sponsor
- University of California, San Francisco
Neuroblastoma, High-risk Neuroblastoma
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
This is a randomized Phase II trial evaluating the addition of the Pediatric Cancer Resource Equity (PediCARE) health equity intervention to usual supportive care for poverty-exposed children with newly diagnosed high-risk…
- Conditions
- Neuroblastoma, High-risk Neuroblastoma, Pediatric Cancer, Disparities
- Trial name
- NCT06335745
- Testing
- PediCARE Intervention
- Sponsor
- Dana-Farber Cancer Institute
High-Risk Neuroblastoma
Naxitamab and GM-CSF in People With Neuroblastoma
This is an Expanded Access Program (EAP) that will give the participants access to the drug naxitamab before it is approved by the FDA. Naxitamab will be combined with granulocyte-macrophage colony stimulating factor (GM-CSF).
- Trial name
- NCT04501757
- Testing
- Naxitamab/GM-CSF
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
High-Risk Neuroblastoma
Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease
Safety evaluation and initial efficacy evaluation will be conducted in a group of patients as a non-commercial, open-label clinical trial of dinutuximab beta (Qarziba) phase IIa.
- Trial name
- ChIm-NB-PL (NCT05272371)
- Testing
- Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Jagiellonian University
Recurrent Stage IV High Risk Neuroblastoma
Study on Sintilimab in Stage IV High Risk Neuroblastoma
A phase I observational study on the safety and efficacy of treatment of recurrent stage IV high risk neuroblastoma with Nivolumab
- Trial name
- SCMC-S-2020 (NCT04412408)
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Children's Medical Center
High Risk Neuroblastoma
Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma
The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCT including high-dose 131I-metaiodobenzylguanidine (MIBG) treatment.
- Trial name
- NCT03061656
- Testing
- Cyclophosphamide, Carboplatin, Etoposide
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Neuroblastoma, Lymphoma
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
This is a pilot clinical trial investigating the addition of haploidentical natural killer cell infusion to autologous stem cell transplantation.
- Conditions
- Neuroblastoma, Lymphoma, High-risk Tumor
- Trial name
- NCT02130869
- Testing
- CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Jude Children's Research Hospital
Newly Diagnosed High Risk Neuroblastoma
Response-based Treatment of High-risk Neuroblastoma
The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.
- Trial name
- NCT02771743
- Testing
- Cisplatin, Doxorubicin, Etoposide
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Samsung Medical Center